Changeflow GovPing Pharma & Drug Safety Thiocycloheptyne Derivatives and Their Use
Routine Rule Added Final

Thiocycloheptyne Derivatives and Their Use

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published European patent application EP3820858A1 for thiocycloheptyne derivatives and their pharmaceutical use, filed by Cristal Delivery B.V. The patent covers thiocycloheptyne compound compositions and their therapeutic applications under IPC classification A61K. The patent is validated in all designated EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and 24 other jurisdictions.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO granted European patent EP3820858A1 for thiocycloheptyne derivatives and their therapeutic use. The patent is classified under IPC codes covering pharmaceutical compositions (A61K47/54, A61K47/58, A61K47/62, A61K47/69), chemical compounds (C07D 333/04, C07D 333/06, C07D 333/08), and diagnostic methods (G01N 33/543, G01N 33/53), indicating broad application across drug delivery and diagnostics.

Pharmaceutical companies developing sulfur-containing therapeutics or drug delivery systems in the EU must consider this patent when assessing freedom to operate. Competitors may seek licensing arrangements with Cristal Delivery or design around the claimed compounds to avoid infringement.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

THIOCYCLOHEPTYNE DERIVATIVES AND THEIR USE

Publication EP3820858A1 Kind: A1 Apr 08, 2026

Applicants

Cristal Delivery B.V.

Inventors

WETERINGS, Josephus Johannes, RIJCKEN, Cristianne Johanna Ferdinand

IPC Classifications

C07D 333/04 20060101AFI20200117BHEP C07D 333/06 20060101ALI20200117BHEP C07D 333/08 20060101ALI20200117BHEP G01N 33/543 20060101ALI20200117BHEP C12Q 1/6876 20180101ALI20200117BHEP G01N 33/53 20060101ALI20200117BHEP C07K 1/13 20060101ALI20200117BHEP A61K 47/54 20170101ALI20200117BHEP A61K 47/58 20170101ALI20200117BHEP A61K 47/62 20170101ALI20200117BHEP A61K 47/69 20170101ALI20200117BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3820858A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Pharmaceutical IP Drug composition
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!